FN2 Research
Markets, explained.
Cited, no-noise breakdowns of why stocks move — earnings reactions, macro shifts, and the data behind the headlines.
Markets Whipsawed by Iran Deal Headlines as Conflict Widens on Multiple Fronts
Markets surged on Treasury Secretary Bessent's claim a Hormuz deal was imminent, then reversed as Iran's draft plan would ban U.S. ships. Meanwhile, Houthis struck Saudi Arabia, Riyadh signed a NATO-style defense pact with Turkey and Pakistan, and U.S.-China trade retaliation widened ahead of Xi's September visit.
The S&P 500's Record Week Was Bought With a Hall-of-Mirrors Jobs Report
The S&P 500 closed at a record high on Friday, capping its best week since April. A dovish — but distorted — July jobs report powered the rally, yet labor force participation at 50-year lows and consumer sentiment near 50 argue the foundation has cracks the equity market isn't pricing.
Lockup Tsunami Meets Biotech IPO Wave as Market Absorption Tested
SpaceX's $100B lockup expiry, Figma's $1.9B unlock, and the busiest biotech IPO week since April are arriving in the same window. The cumulative absorption test is whether demand keeps pace with expanding supply.
Record Highs Meet a 2006 Echo: The Tape Is Pricing a Soft Landing the Bond Market Doesn't Believe
The S&P 500 and Dow closed at record highs as Iran diplomacy, Q2 earnings growth near 48%, and a soft payrolls report combined to clear key resistance. A rising 30-year yield and a 2006-vintage macro analog complicate the bull case.
The IPO Supply Pipe Opens: SpaceX Lockups Expire as $700 Billion in 2026 Issuance Tests the Market
SpaceX's first lockup expiry freed 911 million shares. Goldman Sachs says 2026 issuance has reached $700 billion. Ninety One warns the AI listing wave could reverse a de-equitisation tailwind that added 0.7% annually to US equity returns. Here is what the supply pipeline looks like and what to watch next.
Two Fronts, One Risk Premium: Hormuz Chokehold Meets Polysilicon Tariffs as Geopolitical Pressure Compounds
Strait of Hormuz shipping traffic has collapsed to 10% of pre-war levels while a new 15% polysilicon tariff targets China's chip and solar supply chain — two geopolitical escalations hitting energy and semiconductors simultaneously, and neither shows signs of de-escalating.
Biotech Floods the August IPO Window While the SEC Rethinks 20 Years of Market Structure
Six biotech IPOs priced in the first week of August, and July's $29.3 billion in new listings was the busiest July in a decade. But the SEC's June proposal to rescind Regulation NMS Rule 611 could quietly reshape the plumbing underneath it all.
Two Oil Chokepoints Squeezed at Once: Hormuz at a Trickle, Senate Votes 100% Tariffs on Russian Oil Buyers
Iran's blockade of the Strait of Hormuz has cut tanker transits to a trickle while the Senate's Graham Act threatens 100% tariffs on the top five buyers of Russian oil. Two energy chokepoints under simultaneous pressure, a new regional military pact, and record equities — a divergence worth watching.
The Soft-Jobs Paradox: S&P 500 at a Record, but the Labor Market Just Cracked
The U.S. economy shed 23,000 jobs in July against expectations for 83,000 added. The S&P 500 closed at a fresh all-time high. Semiconductors, gold, and software led the rally while The Trade Desk cratered on its slowest revenue growth since 2020. The 30-year Treasury yield sits near a 19-year high.
Biotech IPOs Surge Into August as SpaceX Lockup Tests the Float
The August IPO window is opening wider than expected, with four biotechs raising $1.17 billion — all upsized. SpaceX's staggered lockup expiry could more than double the float, and the SEC's proposed rescission of Reg NMS Rule 611 looms as the most significant market-structure change in two decades.
S&P 500 Record Close Caps Best Week Since April as Jobs Miss Defuses Fed-Hike Risk
The Nasdaq's 5.2% weekly surge is one of the cleanest tells in the opening snapshot: a soft payrolls print eased rate-hike pressure just as Q2 earnings beats landed at record margins, lifting semiconductors and AI-software names while energy and financials lagged. The macro analog to 2006 suggests caution, not alarm.
Biotech Leads August's IPO Surge as Issuance Window Swings Wide Open
Six IPOs priced in the first week of August 2026 — four biotechs raising $1.17 billion combined — led by Braveheart Bio's 67% first-week pop. The issuance window is widening even as market-structure shifts reshape liquidity underneath new listings.